Hope S Rugo Selected Research

Hormones (Hormone)

11/2022	The 21-Gene Recurrence Score in Clinically High-Risk Lobular and Ductal Breast Cancer: A National Cancer Database Study.
9/2022	Analysis of patients without and with an initial triple-negative breast cancer diagnosis in the phase 3 randomized ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer.
1/2022	Redefining breast cancer subtypes to guide treatment prioritization and maximize response: Predictive biomarkers across 10 cancer therapies.
1/2022	Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer.
1/2022	Biomarkers for Cyclin-Dependent Kinase 4/6 Inhibitors in the Treatment of Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced/Metastatic Breast Cancer: Translation to Clinical Practice.
1/2022	Overall Survival with Palbociclib and Fulvestrant in Women with HR+/HER2- ABC: Updated Exploratory Analyses of PALOMA-3, a Double-blind, Phase III Randomized Study.
1/2022	Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42/AFT-05/BIG-14-03).
1/2022	Efficacy and Safety of Initial 5 Years of Adjuvant Endocrine Therapy in Postmenopausal Hormone Receptor-Positive Breast Cancer: A Systematic Review and Network Meta-Analysis.
1/2022	Longitudinal Trajectories of Memory Performance in Patients with Early-Stage Breast Cancer.
12/2021	Endocrine Treatment and Targeted Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: ASCO Guideline Update.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Hope S Rugo Research Topics

Disease

232	Breast Neoplasms (Breast Cancer) 11/2022 - 12/2003
137	Neoplasms (Cancer) 11/2022 - 12/2003
35	Triple Negative Breast Neoplasms 09/2022 - 01/2010
20	Neoplasm Metastasis (Metastasis) 09/2022 - 01/2008
20	Disease Progression 01/2022 - 09/2012
15	Neutropenia 01/2021 - 06/2013
12	Nausea 02/2022 - 02/2013
11	Vomiting 01/2021 - 02/2013
10	Diarrhea 02/2022 - 01/2017
10	Fatigue 01/2021 - 02/2012
9	Brain Neoplasms (Brain Tumor) 06/2022 - 01/2009
9	Anemia 01/2022 - 02/2012
9	Stomatitis 01/2018 - 06/2004
8	Circulating Neoplastic Cells 01/2022 - 01/2017
8	Febrile Neutropenia 01/2022 - 10/2013
8	Pathologic Complete Response 12/2021 - 01/2020
6	Alopecia (Baldness) 02/2020 - 01/2017
6	Hypertension (High Blood Pressure) 10/2018 - 01/2004
5	Hyperglycemia 02/2022 - 02/2012
5	Pneumonia (Pneumonitis) 01/2022 - 02/2012
5	Peripheral Nervous System Diseases (PNS Diseases) 01/2020 - 07/2015
4	Exanthema (Rash) 02/2022 - 01/2017
4	Leukemia 01/2021 - 06/2004
4	Proteinuria 01/2016 - 01/2004
3	Cardiotoxicity 02/2022 - 02/2007
3	Interstitial Lung Diseases (Interstitial Lung Disease) 01/2022 - 01/2021
3	Residual Neoplasm 11/2021 - 02/2012
3	Amenorrhea 08/2021 - 06/2015

Drug/Important Bio-Agent (IBA)

93	Hormones (Hormone)IBA 11/2022 - 04/2007
43	ErbB Receptors (EGF Receptor)IBA 01/2022 - 02/2007
32	Trastuzumab (Herceptin)FDA Link 02/2022 - 02/2007
24	Biomarkers (Surrogate Marker)IBA 01/2022 - 01/2008
23	Paclitaxel (Taxol)FDA LinkGeneric 02/2022 - 10/2006
22	human ERBB2 proteinIBA 01/2022 - 02/2011
21	palbociclibIBA 01/2022 - 01/2016
19	taxaneIBA 10/2021 - 02/2005
19	Bevacizumab (Avastin)FDA Link 01/2020 - 01/2004
18	Everolimus FDA Link 01/2021 - 06/2009
18	Aromatase InhibitorsIBA 01/2021 - 07/2007
17	Capecitabine (Xeloda)FDA Link 10/2021 - 02/2005
17	Estrogen ReceptorsIBA 10/2021 - 06/2009
15	exemestane (Aromasin)FDA Link 01/2021 - 02/2012
14	Letrozole (Femara)FDA LinkGeneric 01/2021 - 06/2009
13	AnthracyclinesIBA 07/2019 - 02/2005
12	Fulvestrant (Faslodex)FDA Link 01/2022 - 02/2016
11	Estrogens (Estrogen)FDA Link 05/2020 - 04/2007
11	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2020 - 01/2004
10	Cyclin-Dependent Kinase 4IBA 01/2022 - 02/2016
10	Lapatinib (GW572016)FDA Link 01/2020 - 02/2007
9	Pharmaceutical PreparationsIBA 01/2022 - 08/2005
9	Epidermal Growth Factor (EGF)IBA 01/2022 - 03/2010
9	130-nm albumin-bound paclitaxelIBA 11/2021 - 07/2015
9	Carboplatin (JM8)FDA LinkGeneric 11/2021 - 04/2005
9	Tyrosine Kinase InhibitorsIBA 01/2021 - 10/2006
8	AlpelisibIBA 02/2022 - 01/2018
8	pembrolizumabIBA 01/2021 - 08/2017
7	sacituzumab govitecanIBA 09/2022 - 01/2019
7	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 01/2022 - 08/2005
7	etirinotecan pegolIBA 01/2022 - 11/2015
7	B7-H1 AntigenIBA 11/2021 - 08/2017
7	abemaciclibIBA 03/2021 - 02/2016
7	Gemcitabine FDA Link 01/2021 - 05/2013
7	TOR Serine-Threonine KinasesIBA 01/2020 - 02/2012
7	Biological ProductsIBA 01/2020 - 09/2010
7	Monoclonal AntibodiesIBA 01/2018 - 01/2004
6	Ado-Trastuzumab EmtansineIBA 02/2022 - 02/2011
6	Poly(ADP-ribose) Polymerase InhibitorsIBA 01/2022 - 01/2018
6	talazoparibIBA 01/2022 - 01/2018
6	Immune Checkpoint InhibitorsIBA 01/2022 - 12/2016
6	Phenobarbital (Luminal)FDA Link 11/2020 - 11/2011
6	Progesterone Receptors (Progesterone Receptor)IBA 01/2020 - 04/2007
6	ixabepilone (BMS 247550)FDA Link 01/2020 - 06/2013
5	PlatinumIBA 11/2021 - 06/2015
5	Cyclophosphamide (Cytoxan)FDA LinkGeneric 11/2021 - 02/2007
5	Vinorelbine (Navelbine)FDA LinkGeneric 01/2021 - 01/2004
4	atezolizumabIBA 11/2021 - 11/2018
4	Doxorubicin (Adriamycin)FDA LinkGeneric 11/2021 - 02/2007
4	neratinibIBA 10/2021 - 05/2019
4	eribulin FDA Link 01/2021 - 09/2017
4	Immunoconjugates (Immunoconjugate)IBA 01/2021 - 02/2011
4	Phosphatidylinositol 3-Kinase (1 Phosphatidylinositol 3 Kinase)IBA 01/2020 - 02/2016
4	Progesterone FDA LinkGeneric 01/2020 - 01/2010
4	SteroidsIBA 01/2020 - 01/2016
4	Palonosetron (Aloxi)FDA Link 01/2019 - 02/2013
4	Angiogenesis InhibitorsIBA 10/2018 - 08/2005
4	LigandsIBA 01/2018 - 01/2004
3	Proteins (Proteins, Gene)FDA Link 01/2022 - 10/2021
3	Circulating Tumor DNAIBA 01/2022 - 01/2018
3	olaparibIBA 12/2021 - 06/2021
3	veliparibIBA 11/2021 - 07/2016
3	Biosimilar PharmaceuticalsIBA 07/2021 - 05/2016
3	ribociclibIBA 01/2021 - 02/2016
3	Irinotecan (Camptosar)FDA LinkGeneric 01/2021 - 01/2019

Therapy/Procedure

127	Therapeutics 06/2022 - 12/2003
98	Drug Therapy (Chemotherapy) 11/2022 - 12/2003
28	Neoadjuvant Therapy 02/2022 - 12/2004
11	Drug Tapering 01/2021 - 08/2005
8	Adjuvant Chemotherapy 06/2022 - 12/2003
6	Aftercare (After-Treatment) 01/2018 - 11/2011
3	Immunotherapy 01/2022 - 01/2021